MediciNova Inc. (MNOV) announced Thursday morning that it has received Fast Track designation from the FDA for MN-001, for the treatment of patients with nonalcoholic steatohepatitis with fibrosis.
MediciNova gapped open sharply higher Thursday, but traded in a range for the majority of the session. The stock ended the day with a gain of 1.45 at $4.96 on the highest volume of the year. MediciNova jumped to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News